Grant: CIHR Fellowship
Direct Payment
$60,000.00
Impact of airway pathogen clusters on clinical outcomes in cystic fibrosis
FY 2015-16
Summary
Background: Cystic fibrosis (CF) is the most common lethal genetic disease affecting Caucasians. CF is notorious for chronic progressive respiratory infections and 90% of individuals succumb to complications of end stage lung disease. Chronic airway infection is the leading cause of lung function decline.
Pseudomonas aeruginosa is the prototypical CF pathogen and eventually infects up to 70% of individuals. Furthermore, chronic P. aeruginosa infection is associated with increased risk of end-stage lung disease, and worsened survival. However, patients are frequently infected with other bacteria, including Staphylococcus aureus, Haemophilus influenzae, Burkholderia species, Stenotrophomonas maltophilia, and Achromobacter xylosoxidans; which may impact outcomes. These organisms may have direct or indirect pathogenicity. Unfortunately, much of our understanding of outcomes of CF airways infections is based on studying pathogens in isolation which overlooks the potential impacts of interactions between bacterial communities. Thus, an understanding of how clusters of organisms impact disease may have important future implications on how we manage airway infections in CF.
Objective: Our study will use longitudinal data from ~25,000 individuals with CF from the US Cystic Foundation Registry to determine: 1.Do specific clusters of bacteria (including P. aeruginosa) cause chronic infections with CF airways?, and 2.Do patient outcomes differ based on the clusters of bacterial pathogens in their airways?
Protocol: We plan to use an unbiased approach to assess the presence, and clinical outcomes of unique bacterial pathogen clusters. As it has already been established that chronic P. aeruginosa causes worsened outcomes in CF, we hope to determine if different groups of bacteria (in addition to Pseudomonas) modify important clinical outcomes including time to death or lung transplantation, rate of lung function decline, and frequency of pulmonary (infectious) exacerbation.
Department
Program
CIHR Fellowship
Recipient
Location
Washington, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
339109
Name
Somayaji Ranjani
Region
Washington
Country
United States of America
Orgtype
Research Institution
Instname2
Infection and Immunity
Theme2
Clinical
Prcname2
Health Professional Awards - Fellowships
Projecttitle
Impact of airway pathogen clusters on clinical outcomes in cystic fibrosis
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$60,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Bacterial Infection; Clinical Epidemiology; Cluster Algorithms; Cystic Fibrosis; Outcomes Research
Abstract
Background: Cystic fibrosis (CF) is the most common lethal genetic disease affecting Caucasians. CF is notorious for chronic progressive respiratory infections and 90% of individuals succumb to complications of end stage lung disease. Chronic airway infection is the leading cause of lung function decline.
Pseudomonas aeruginosa is the prototypical CF pathogen and eventually infects up to 70% of individuals. Furthermore, chronic P. aeruginosa infection is associated with increased risk of end-stage lung disease, and worsened survival. However, patients are frequently infected with other bacteria, including Staphylococcus aureus, Haemophilus influenzae, Burkholderia species, Stenotrophomonas maltophilia, and Achromobacter xylosoxidans; which may impact outcomes. These organisms may have direct or indirect pathogenicity. Unfortunately, much of our understanding of outcomes of CF airways infections is based on studying pathogens in isolation which overlooks the potential impacts of interactions between bacterial communities. Thus, an understanding of how clusters of organisms impact disease may have important future implications on how we manage airway infections in CF.
Objective: Our study will use longitudinal data from ~25,000 individuals with CF from the US Cystic Foundation Registry to determine: 1.Do specific clusters of bacteria (including P. aeruginosa) cause chronic infections with CF airways?, and 2.Do patient outcomes differ based on the clusters of bacterial pathogens in their airways?
Protocol: We plan to use an unbiased approach to assess the presence, and clinical outcomes of unique bacterial pathogen clusters. As it has already been established that chronic P. aeruginosa causes worsened outcomes in CF, we hope to determine if different groups of bacteria (in addition to Pseudomonas) modify important clinical outcomes including time to death or lung transplantation, rate of lung function decline, and frequency of pulmonary (infectious) exacerbation.
Competitiondate
201511
Approvedterm2
1 yr 0 mth
Pinamesdelim
Somayaji, Ranjani
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $60,000~ $0~